AngioDynamics, Inc. (ANGO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q1 FY2027, filed Oct 8, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ANGO SEC filings page.
AngioDynamics, Inc. (ANGO) reported $325.4M in revenue over the twelve months to Aug 31, 2026, up 8.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue recovery is reaching cash flow, but recurring losses still erode equity despite modest margin improvement.
Cash conversion improved: operating cash flow moved from-$10.1M in FY2025 to$3.1M in FY2026, while free cash flow also turned positive. However, accounting profitability has not followed; the company still recorded a net loss of$36.7M , so the cash improvement reflects better cash timing and noncash expense effects rather than a completed earnings turnaround.
Gross margin increased from
Assets declined from
Financial Health Signals
Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of AngioDynamics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
AngioDynamics, Inc. has an operating margin of -12.5%, meaning the company loses $12 on every $100 of revenue. This results in a profitability score of 17/100. This is up from -13.7% the prior year.
AngioDynamics, Inc.'s revenue grew 9.5% year-over-year to $320.2M, a solid pace of expansion. This earns a growth score of 40/100.
AngioDynamics, Inc. has a moderate D/E ratio of 0.56. This balance of debt and equity financing earns a leverage score of 58/100.
AngioDynamics, Inc.'s current ratio of 2.19 indicates adequate short-term liquidity, earning a score of 64/100. The company can meet its near-term obligations, though with limited headroom.
While AngioDynamics, Inc. generated $3.1M in operating cash flow, capex of $2.6M consumed most of it, leaving $508K in free cash flow. This results in a low score of 18/100, reflecting heavy capital investment rather than weak cash generation.
AngioDynamics, Inc. posts a -21.5% return on equity (ROE), meaning it loses $22 for every $100 of shareholders' equity. This results in a returns score of 16/100. This is down from -18.6% the prior year.
AngioDynamics, Inc. scores 1.52, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($458.4M) relative to total liabilities ($96.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
AngioDynamics, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
AngioDynamics, Inc. reported a net loss of $36.7M while generating $3.1M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
AngioDynamics, Inc. reported an operating loss of $39.9M against $299K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
AngioDynamics, Inc. generated $80.9M in revenue in Q1 2027. This represents an increase of 6.9% from the same quarter a year earlier. Against the prior quarter it is down 6.6%.
AngioDynamics, Inc.'s EBITDA was -$1.8M in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 61.7% from the same quarter a year earlier. Against the prior quarter it is up 60.8%.
AngioDynamics, Inc. reported -$7.1M in net income in Q1 2027. This represents an increase of 34.9% from the same quarter a year earlier. Against the prior quarter it is up 37.8%.
AngioDynamics, Inc. earned -$0.17 per diluted share (EPS) in Q1 2027. This represents an increase of 34.6% from the same quarter a year earlier. Against the prior quarter it is up 37.0%.
Cash & Balance Sheet
AngioDynamics, Inc. recorded an outflow of $15.7M in free cash flow in Q1 2027, representing a cash shortfall after capex. This represents an increase of 5.6% from the same quarter a year earlier. Against the prior quarter it is down 192.2%.
AngioDynamics, Inc. held $34.0M in cash as of Q1 2027; long-term debt is not reported for that period.
Not reported for Q1 2027.
Margins & Returns
AngioDynamics, Inc.'s gross margin was 59.4% in Q1 2027, indicating the percentage of revenue retained after direct costs. This is up 4.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.4 percentage points.
AngioDynamics, Inc.'s operating margin was -9.0% in Q1 2027, reflecting core business profitability. This is up 5.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.7 percentage points.
AngioDynamics, Inc.'s net profit margin was -8.8% in Q1 2027, showing the share of revenue converted to profit. This is up 5.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.4 percentage points.
AngioDynamics, Inc.'s ROE was -4.3% in Q1 2027, measuring profit generated per dollar of shareholder equity. This is up 1.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.3 percentage points.
Capital Allocation
AngioDynamics, Inc. invested $8.0M in research and development in Q1 2027. This represents an increase of 24.3% from the same quarter a year earlier. Against the prior quarter it is down 2.4%.
AngioDynamics, Inc. invested $379K in capex in Q1 2027, funding long-term assets and infrastructure. This represents a decrease of 48.2% from the same quarter a year earlier. Against the prior quarter it is down 8.2%.
Not reported for Q1 2027.
ANGO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $80.9M+6.9% | $86.6M+8.0% | $78.4M+8.9% | $79.4M+9.0% | $75.7M+12.2% | $80.2M+12.9% | $72.0M-4.2% | $72.8M-7.9% |
| Cost of Revenue | $32.9M-2.9% | $39.8M+5.0% | $36.9M+11.5% | $34.6M+5.2% | $33.9M+10.0% | $37.9M+16.9% | $33.1M-15.7% | $32.9M-15.1% |
| Gross Profit | $48.0M+14.8% | $46.8M+10.8% | $41.5M+6.7% | $44.8M+12.2% | $41.9M+14.0% | $42.2M+9.6% | $38.9M+8.4% | $39.9M-0.9% |
| R&D Expenses | $8.0M+24.3% | $8.2M+24.1% | $7.1M+2.5% | $7.8M+20.7% | $6.4M+2.1% | $6.6M-2.0% | $6.9M-15.6% | $6.4M-25.7% |
| SG&A Expenses | $12.5M-0.7% | $10.3M+0.3% | $10.7M+2.2% | $10.2M-2.3% | $12.6M+14.4% | $10.2M-2.0% | $10.5M-0.8% | $10.4M+11.9% |
| Operating Income | -$7.3M+31.5% | -$10.2M-76.1% | -$13.0M-29.8% | -$6.1M+44.8% | -$10.7M+18.6% | -$5.8M+59.9% | -$10.0M+95.0% | -$11.1M+15.4% |
| EBITDA | -$1.8M+61.7% | -$4.6M-10317.8% | -$7.4M-101.4% | -$308K+92.7% | -$4.7M+25.5% | $45K+100.6% | -$3.7M+98.1% | -$4.2M+34.3% |
| Interest Expense | $88K+2100.0% | $105K | $88K | $102K | $4K | N/A | N/A | N/A |
| Income Tax | -$199K-406.2% | $370K+716.7% | $12K+700.0% | -$5K+95.5% | $65K-51.1% | -$60K+91.3% | -$2K+100.0% | -$110K-100.7% |
| Net Income | -$7.1M+34.9% | -$11.4M-88.5% | -$8.1M-83.4% | -$6.3M+40.9% | -$10.9M+14.8% | -$6.0M+55.0% | -$4.4M+97.7% | -$10.7M+63.0% |
| EPS (Basic) | -$0.17+34.6% | -$0.27-80.0% | -$0.19-72.7% | -$0.15+42.3% | -$0.26+16.1% | -$0.15+54.5% | -$0.11+97.6% | -$0.26+63.9% |
| EPS (Diluted) | -$0.17+34.6% | -$0.27-80.0% | -$0.19-72.7% | -$0.15+42.3% | -$0.26+16.1% | -$0.15+54.5% | -$0.11+97.6% | -$0.26+63.9% |
| Diluted Shares (Avg) | 42M+2.1% | N/A | 42M+1.8% | 42M+1.5% | 41M+1.3% | N/A | 41M+1.5% | 41M+1.7% |
ANGO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $241.9M-8.9% | $267.2M-4.6% | $260.7M-8.7% | $269.7M-7.5% | $265.6M-9.5% | $280.1M-11.8% | $285.4M-12.1% | $291.6M-41.6% |
| Current Assets | $143.0M-8.7% | $163.4M-2.9% | $155.6M-9.7% | $161.3M-8.0% | $156.7M-9.2% | $168.3M-12.9% | $172.3M-12.5% | $175.4M-5.4% |
| Cash & Equivalents | $34.0M-12.4% | $53.9M-3.6% | $37.8M-15.5% | $41.6M-23.0% | $38.8M-29.5% | $55.9M-26.5% | $44.8M-42.9% | $54.1M-11.2% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $55.0M-11.7% | $52.4M-15.4% | $58.6M-7.2% | $65.6M-0.5% | $62.3M-3.8% | $62.0M+2.3% | $63.1M+8.7% | $65.9M+2.6% |
| Accounts Receivable | $44.9M+5.3% | $48.3M+12.7% | $45.6M+4.8% | $44.4M+3.0% | $42.6M+7.8% | $42.9M-1.7% | $43.5M-12.1% | $43.2M-16.4% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $78.0M-10.2% | $96.3M-0.9% | $87.3M-12.3% | $93.3M-10.9% | $86.8M-10.6% | $97.2M-13.3% | $99.5M-6.2% | $104.8M+6.5% |
| Current Liabilities | $59.7M-12.6% | $74.7M-1.9% | $66.1M-15.3% | $72.0M-18.8% | $68.3M-11.0% | $76.2M-16.4% | $78.0M-9.2% | $88.6M+13.5% |
| Non-Current Liabilities | $18.3M-1.2% | $21.6M+3.1% | $21.3M-1.5% | $21.4M+32.1% | $18.5M-9.1% | $21.0M+0.2% | $21.6M+6.4% | $16.2M-20.5% |
| Total Equity | $164.0M-8.3% | $170.8M-6.6% | $173.4M-6.7% | $176.3M-5.6% | $178.9M-9.0% | $183.0M-11.0% | $185.9M-15.0% | $186.8M-53.5% |
| Retained Earnings | -$473.0M-7.5% | -$465.9M-8.6% | -$454.5M-7.4% | -$446.4M-6.6% | -$440.1M-7.9% | -$429.2M-8.6% | -$423.1M-10.8% | -$418.7M-115.8% |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
ANGO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$15.3M+3.7% | $17.5M-7.2% | -$3.1M+76.4% | $4.7M+88.5% | -$15.9M+12.8% | $18.8M+276.1% | -$13.2M-5.1% | $2.5M-53.0% |
| Depreciation & Amortization | $5.5M-7.6% | $5.6M-4.0% | $5.6M-11.5% | $5.8M-15.2% | $6.0M-12.3% | $5.8M-14.4% | $6.3M-16.0% | $6.9M+2.7% |
| Stock-Based Compensation | $4.5M+0.7% | N/A | $2.7M+12.5% | $2.9M+16.0% | $4.5M+39.5% | N/A | $2.4M-7.7% | $2.5M+31.6% |
| Capital Expenditures | $379K-48.2% | $413K-46.8% | $1.0M-43.5% | $422K-47.1% | $731K-33.1% | $777K+37.3% | $1.8M+196.2% | $797K+43.9% |
| Free Cash Flow | -$15.7M+5.6% | $17.0M-5.5% | -$4.1M+72.4% | $4.2M+152.9% | -$16.6M+14.0% | $18.0M+306.6% | -$15.0M-13.9% | $1.7M-64.4% |
| Investing Cash Flow | -$3.1M-103.0% | -$1.3M+51.6% | -$1.5M+52.7% | -$1.6M+17.3% | -$1.6M+35.5% | -$2.6M-12.3% | -$3.2M-110.8% | -$2.0M-9.4% |
| Financing Cash Flow | -$1.4M-1061.5% | -$108K+98.1% | $621K-91.3% | -$92K+91.8% | $143K+128.1% | -$5.8M-15.4% | $7.1M+929.8% | -$1.1M-219.0% |
| Share Buybacks | N/A | $0 | $0 | $0-100.0% | $0-100.0% | $0 | $0 | $1.1M |
Not reported in any period shown, so not listed: Dividends Paid.
ANGO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.4%+4.1pp | 54.0%+1.3pp | 52.9%-1.1pp | 56.4%+1.6pp | 55.3%+0.9pp | 52.7%-1.6pp | 54.0%+6.3pp | 54.8%+3.9pp |
| Operating Margin | -9.0%+5.0pp | -11.8%-4.5pp | -16.5%-2.7pp | -7.7%+7.5pp | -14.1%+5.3pp | -7.2%+13.1pp | -13.9% | -15.2%+1.4pp |
| Net Margin | -8.8%+5.6pp | -13.2%-5.6pp | -10.3%-4.2pp | -8.0%+6.8pp | -14.4%+4.6pp | -7.5%+11.4pp | -6.1% | -14.7%+22.0pp |
| Return on Equity | -4.3%+1.8pp | -6.7%-3.4pp | -4.7%-2.3pp | -3.6%+2.2pp | -6.1%+0.4pp | -3.3%+3.2pp | -2.4%+83.5pp | -5.8%+1.5pp |
| Return on Assets | -2.9%+1.2pp | -4.3%-2.1pp | -3.1%-1.6pp | -2.4%+1.3pp | -4.1%+0.3pp | -2.2%+2.1pp | -1.5%+56.3pp | -3.7%+2.1pp |
| Current Ratio | 2.40+0.1x | 2.190.0x | 2.35+0.1x | 2.24+0.3x | 2.290.0x | 2.21+0.1x | 2.21-0.1x | 1.98-0.4x |
| Debt-to-Equity | 0.480.0x | 0.560.0x | 0.500.0x | 0.530.0x | 0.490.0x | 0.53+0.5x | 0.54+0.1x | 0.56+0.3x |
| Asset Turnover | 0.330.0x | 0.320.0x | 0.300.0x | 0.290.0x | 0.28+0.1x | 0.29+0.1x | 0.250.0x | 0.25+0.1x |
| FCF Margin | -19.4%+2.6pp | 19.7%-2.8pp | -5.3%+15.5pp | 5.3%+3.0pp | -22.0%+6.7pp | 22.5%+16.3pp | -20.8%-3.3pp | 2.3%-3.7pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| AngioDynamics, Inc. ANGO | FY2026 | $320.2M | -$36.7M | -11.5% | $458.4M | 36/100 |
| Sanara MedTech Inc. SMTI | FY2025 | $103.1M | $37.6M | 36.4% | $323.0M | 45/100 |
| Embecta Corp. EMBC | FY2025 | $1.1B | $95.4M | 8.8% | $339.4M | 57/100 |
| Kestra Medical Technologies, Ltd. KMTS | FY2026 | $95.1M | -$131.6M | N/A | $1.6B | 50/100 |
| Staar Surgical Co STAA | FY2025 | $239.4M | -$80.4M | -33.6% | $1.1B | 33/100 |
| AtriCure, Inc. ATRC | FY2025 | $534.5M | -$11.4M | -2.1% | $2.9B | 57/100 |
Where AngioDynamics, Inc. Ranks
Frequently Asked Questions
What is AngioDynamics, Inc.'s annual revenue?
AngioDynamics, Inc. (ANGO) reported $320.2M in total revenue for fiscal year 2026. This represents a 9.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is AngioDynamics, Inc.'s revenue growing?
AngioDynamics, Inc. (ANGO) revenue grew by 9.5% year-over-year, from $292.5M to $320.2M in fiscal year 2026.
Is AngioDynamics, Inc. profitable?
No, AngioDynamics, Inc. (ANGO) reported a net income of -$36.7M in fiscal year 2026, with a net profit margin of -11.5%.
What is AngioDynamics, Inc.'s EBITDA?
AngioDynamics, Inc. (ANGO) had EBITDA of -$17.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is AngioDynamics, Inc.'s gross margin?
AngioDynamics, Inc. (ANGO) had a gross margin of 54.6% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is AngioDynamics, Inc.'s operating margin?
AngioDynamics, Inc. (ANGO) had an operating margin of -12.5% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is AngioDynamics, Inc.'s net profit margin?
AngioDynamics, Inc. (ANGO) had a net profit margin of -11.5% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
What is AngioDynamics, Inc.'s return on equity (ROE)?
AngioDynamics, Inc. (ANGO) has a return on equity of -21.5% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is AngioDynamics, Inc.'s free cash flow?
AngioDynamics, Inc. (ANGO) generated $508K in free cash flow during fiscal year 2026. This represents a 103.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is AngioDynamics, Inc.'s operating cash flow?
AngioDynamics, Inc. (ANGO) generated $3.1M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
What are AngioDynamics, Inc.'s total assets?
AngioDynamics, Inc. (ANGO) had $267.2M in total assets as of fiscal year 2026, including both current and long-term assets.
What are AngioDynamics, Inc.'s capital expenditures?
AngioDynamics, Inc. (ANGO) invested $2.6M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does AngioDynamics, Inc. spend on research and development?
AngioDynamics, Inc. (ANGO) invested $29.4M in research and development during fiscal year 2026.
What is AngioDynamics, Inc.'s current ratio?
AngioDynamics, Inc. (ANGO) had a current ratio of 2.19 as of fiscal year 2026, which is generally considered healthy.
What is AngioDynamics, Inc.'s debt-to-equity ratio?
AngioDynamics, Inc. (ANGO) had a debt-to-equity ratio of 0.56 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is AngioDynamics, Inc.'s return on assets (ROA)?
AngioDynamics, Inc. (ANGO) had a return on assets of -13.8% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is AngioDynamics, Inc.'s P/E ratio?
AngioDynamics, Inc. (ANGO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to August 31, 2026). The market capitalization is $458.4M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is AngioDynamics, Inc.'s price-to-sales ratio?
AngioDynamics, Inc. (ANGO) trades at 1.4x sales, its market capitalization divided by revenue of $325.4M revenue, trailing 12 months to August 31, 2026. The market capitalization is $458.4M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is AngioDynamics, Inc.'s Altman Z-Score?
AngioDynamics, Inc. (ANGO) has an Altman Z-Score of 1.52, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is AngioDynamics, Inc.'s Piotroski F-Score?
AngioDynamics, Inc. (ANGO) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are AngioDynamics, Inc.'s earnings high quality?
AngioDynamics, Inc. (ANGO) reported a net loss of $36.7M while generating $3.1M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can AngioDynamics, Inc. cover its interest payments?
AngioDynamics, Inc. (ANGO) reported an operating loss of $39.9M against $299K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is AngioDynamics, Inc.?
AngioDynamics, Inc. (ANGO) scores 36 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.